Pro-Dex, Inc. (NASDAQ:PDEX) Short Interest Update

Pro-Dex, Inc. (NASDAQ:PDEX) saw a large increase in short interest in February. As of February 15th, there was short interest totalling 21,600 shares, an increase of 20.7% from the January 31st total of 17,900 shares. Based on an average trading volume of 29,700 shares, the days-to-cover ratio is currently 0.7 days. Currently, 1.0% of the company’s stock are short sold.

Pro-Dex Stock Down 1.5 %

PDEX traded down $0.53 during trading on Thursday, reaching $33.82. The company had a trading volume of 15,763 shares, compared to its average volume of 27,624. The business’s fifty day moving average price is $40.44 and its 200 day moving average price is $37.04. The company has a market cap of $110.29 million, a P/E ratio of 16.83 and a beta of 0.53. The company has a debt-to-equity ratio of 0.33, a current ratio of 2.58 and a quick ratio of 1.44. Pro-Dex has a 12 month low of $16.83 and a 12 month high of $59.60.

Pro-Dex (NASDAQ:PDEX) last posted its quarterly earnings data on Thursday, January 30th. The medical instruments supplier reported $0.61 earnings per share for the quarter, topping the consensus estimate of $0.38 by $0.23. Pro-Dex had a return on equity of 21.68% and a net margin of 11.06%. Equities analysts anticipate that Pro-Dex will post 2 EPS for the current year.

Wall Street Analysts Forecast Growth

PDEX has been the topic of several analyst reports. Ascendiant Capital Markets increased their target price on shares of Pro-Dex from $30.00 to $52.00 and gave the stock a “buy” rating in a research report on Monday, November 11th. StockNews.com downgraded Pro-Dex from a “strong-buy” rating to a “buy” rating in a report on Monday, February 3rd.

Insider Buying and Selling at Pro-Dex

In other Pro-Dex news, Director Raymond E. Cabillot sold 1,200 shares of the stock in a transaction that occurred on Friday, January 10th. The shares were sold at an average price of $47.76, for a total value of $57,312.00. Following the completion of the sale, the director now owns 359,646 shares in the company, valued at $17,176,692.96. This represents a 0.33 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders have sold a total of 27,770 shares of company stock valued at $1,239,312 in the last 90 days. 47.50% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. EAM Investors LLC acquired a new stake in shares of Pro-Dex during the 4th quarter worth approximately $1,047,000. O Shaughnessy Asset Management LLC purchased a new position in shares of Pro-Dex during the 4th quarter valued at $995,000. 683 Capital Management LLC purchased a new stake in Pro-Dex in the fourth quarter valued at approximately $739,000. Ritholtz Wealth Management bought a new stake in Pro-Dex during the fourth quarter worth about $572,000. Finally, American Century Companies Inc. purchased a new position in shares of Pro-Dex during the fourth quarter worth approximately $558,000. 15.28% of the stock is owned by institutional investors.

Pro-Dex Company Profile

Pro-Dex, Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.